Gladstone NOW: The Campaign Join Us on the Journey✕
1 - 15 of 15 Results Clear All
Demystify the chalk talk and set yourself up for success.
Postdoctoral and Graduate Student Education and Research Development Affairs Graduate Students and Postdocs Mahley Lab
The 2020 Berkelhammer Scholars break new ground in research on dementias, Parkinson’s disease, and neuropsychiatric disorders
Donor Stories Parkinson’s Disease Alzheimer’s Disease Dementia Neurological Disease Akassoglou Lab Kreitzer Lab Mahley Lab Mucke Lab Nakamura Lab
San Francisco Business Times—Gabaeron, founded by Gladstone President Emeritus Bob Mahley, MD, PhD, and Therini Bio (formerly Medared), founded upon work by Senior Investigator Katarina Akassoglou, PhD, are among Bay Area biotech companies focusing on neurological diseases that collectively raised more than $3 billion from venture capital firms and the public capital markets in 2020.
Gladstone Experts Parkinson’s Disease Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab Mahley Lab
With an estimated 44 million diagnosed with Alzheimer’s disease worldwide, research is moving quickly to better understand the disease.
Gladstone Experts Alzheimer’s Disease Neurological Disease Mahley Lab Mucke Lab
In 2019, Gladstone launched the Responsible Conduct of Research seminar series as part of its comprehensive training program for postdocs and graduate students.
Postdoctoral and Graduate Student Education and Research Development Affairs Graduate Students and Postdocs Institutional News Conklin Lab Mahley Lab
Alzheimer’s News Today—Gladstone scientists recently received $4.8 million from the NIH to study how the protein apoE4 causes neurodegeneration in Alzheimer's disease.
Gladstone Experts Mahley Lab
With $4.8 million from the NIH, Gladstone scientists will investigate how the protein apoE4 causes neurodegeneration in Alzheimer’s disease.
Grants News Release Alzheimer’s Disease Neurological Disease Krogan Lab Mahley Lab
Gladstone started as a single institute in 1979 but has since grown to four institutes which use cutting-edge technology to tackle cardiovascular, neurological, and immunological diseases.
History Cardiovascular Disease Data Science and Biotechnology Neurological Disease Virology Greene Lab Mahley Lab Mucke Lab Pollard Lab Srivastava Lab
Gladstone began as a single entity with a single purpose. But as the scientists followed the science—unencumbered by the red tape of bureaucracy—the purpose, and the focus, grew.
History Institutional News Cardiovascular Disease Data Science and Biotechnology Neurological Disease Virology Finkbeiner Lab Greene Lab Mahley Lab Mucke Lab
As clinical trials in Alzheimer's disease have failed, Gladstone investigators are taking innovative approaches to understanding the disease and finding new therapeutic targets.
Research (Publication) Alzheimer’s Disease Dementia Neurological Disease Huang Lab Mahley Lab Mucke Lab Palop Lab Aging Disease Models
Learn more about Gladstone's founding President in this video celebrating our 40th anniversary.
History Institutional News Mahley Lab
A look at the distinct eras defined by Gladstone’s three presidents
History Institutional News Mahley Lab Srivastava Lab
E-Scape Bio, a Gladstone spin-off company, extends its Series A financing to generate novel therapies to treat neurodegenerative disorders
Huang Lab Mahley Lab Alzheimer’s Disease
SAN FRANCISCO, CA—Alzheimer’s disease is one of the greatest challenges facing modern medicine, but there is new hope in the fight against this deadly disease.
Huang Lab Mahley Lab Neurological Disease Alzheimer’s Disease
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes are recommending a shift in efforts to treat Alzheimer’s disease by developing drugs that target the apoE4 protein, which has long been associated with an increased risk for the disease.
Alzheimer’s Disease Huang Lab Mahley Lab
